Among 289 million adults in 18 European countries, more than 16 million years of life were lost from 2020 through 2022 due to the COVID-19 pandemic, according to a new study published March 11^th in the open-access journal PLOS Medicine by Sara Ahmadi-Abhari of Imperial College London, UK, and colleagues.

A researcher at Osaka Metropolitan University examined the shifts in migration destination determinants of households with children who mentioned the spread of COVID-19 as a migration motive during the pandemic. The results indicated significant shifts with emphasis on the importance of social interaction-related factors.

For many young adults with anxiety sensitivity — the fear of experiencing anxiety symptoms and the negative health, social and emotional outcomes associated with them — alcohol use became a way to cope with those fears. But as a new Concordia study shows, drinking to cope with fears of anxiety probably made them feel worse.

The study, published in the Journal of American College Health, reveals that drinking to cope put young adults with anxiety sensitivity at further risk of problematic drinking and the negative consequences associated with it.

Monoclonal antibodies like etesevimab have lost efficacy against Omicron subvariants, necessitating innovative solutions. George Fu Gao's team developed BAADesign, a strategy combining structural analysis, computational design, and experimental validation to restore antibody activity. Using this method, they reengineered etesevimab into CB6-IV, achieving broad-spectrum neutralization against Omicron subvariants.